Late-stage clinical biopharmaceutical company, SELLAS Life Sciences Group, Inc., is leading the charge in cancer immunotherapy development across various cancer indications in the United States. The company's main focal point is galinpepimut-S (GPS), a unique cancer immunotherapeutic agent that targets the Wilms tumor 1 protein. GPS is in Phase 3 clinical trials for acute myeloid leukemia treatment and Phase 1/2 clinical trials for ovarian cancer treatment. SELLAS also has a strategic collaboration with Merck & Co., Inc. to evaluate GPS in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial, which enrolls patients in up to five cancer indications, including hematologic malignancies and solid tumors. Furthermore, the company is developing and commercializing GFH009, a highly selective small molecule CDK9 inhibitor, under Phase 1 clinical trials, in collaboration with GenFleet Therapeutics (Shanghai), Inc. SELLAS Life Sciences Group's headquarters is situated in New York, New York.
SELLAS Life Sciences Group, Inc.'s ticker is SLS
The company's shares trade on the NASDAQ stock exchange
They are based in Zurich, Switzerland
There are 1-10 employees working at SELLAS Life Sciences Group, Inc.
It is https://www.sellaslifesciences.com/Home/default.aspx
SELLAS Life Sciences Group, Inc. is in the Healthcare sector
SELLAS Life Sciences Group, Inc. is in the Biotechnology industry
The following five companies are SELLAS Life Sciences Group, Inc.'s industry peers: